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Toll-Like Receptor Activation during Cutaneous
Allergen Sensitization Blocks Development of Asthma
through IFN-Gamma-Dependent Mechanisms
Rita Haapakoski1, Piia Karisola1, Nanna Fyhrquist1, Terhi Savinko1, Sari Lehtima¨ki1, Henrik Wolff2,
Antti Lauerma3 and Harri Alenius1
Toll-like receptors (TLRs) are pattern-recognition receptors that have a pivotal role as primary sensors of microbial
products and as initiators of innate and adaptive immune responses. We investigated the role of TLR2, TLR3, and
TLR4 activation during cutaneous allergen sensitization in the modulation of allergic asthma. The results show
that dermal exposure to TLR4 ligand lipopolysaccharide (LPS) or TLR2 ligand Pam3Cys suppresses asthmatic
responses by reducing airway hyperreactivity, mucus production, Th2-type inflammation in the lungs, and IgE
antibodies in serum in a dose-dependent manner. In contrast, TLR3 ligand Poly(I:C) did not protect the mice from
asthmatic symptoms but reduced IgE and induced IgG2a in serum. LPS (especially) and Pam3Cys enhanced the
activation of dermal dendritic cell (DCs) by increasing the expression of CD80 and CD86 but decreased DC
numbers in draining lymph nodes at early time points. Later, these changes in DCs led to an increased number of
CD8þ T cells and enhanced the production of IFN-g in bronchoalveolar lavage fluid. In conclusion, dermal
exposure to LPS during sensitization modulates the asthmatic response by skewing the Th1/Th2 balance toward
Th1 by stimulating the production of IFN-g. These findings support the hygiene hypothesis and pinpoint the
importance of dermal microbiome in the development of allergy and asthma.
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INTRODUCTION
Asthma is a heterogeneous inflammatory disease of the lungs
characterized by mucus hypersecretion, airway inflammation,
bronchial hyperresponsiveness, and Th2 cell infiltration in the
lungs (Cohn et al., 2004). It is estimated that as many as 300
million people suffer from asthma globally, and the number is
increasing especially in the Western countries (Masoli et al.,
2004; von Mutius and Vercelli, 2010). In addition to multiple
genetic factors known to be involved in the pathogenesis of
asthma, environmental factors have also been hypothesized to
contribute to the outcome of asthma. These include, for example,
different allergens, air pollutants, respiratory viruses, and
endotoxins (Holloway et al., 2010).
The hygiene hypothesis suggests that exposure to microbial
infections in early childhood favors the development of Th1-
type immunity and protects from the later development of
the Th2-type phenotype (Strachan, 1989; Ernst and Cormier,
2000; Bach, 2002; Braun-Fahrla¨nder et al., 2002; Yang and
Gao, 2011). Various Toll-like receptors (TLRs) are important
mediators of innate immunity that recognize pathogen-asso-
ciated microbial patterns from microbial and viral products
and activate distinct signaling pathways. Activation of the
innate immune system through TLRs is also linked to the res-
ponses of adaptive immunity and thus may influence the
development of allergic diseases such as asthma (Reijmerink
et al., 2010; Tesse et al., 2011).
The skin barrier of atopic individuals is often disrupted, and
several microbial components and allergens can penetrate
easily through the dermis. In the present study, we investigated
the role of TLR ligands in the development of asthma by
mimicking the natural route of sensitization from the skin to
systemic and airway responses. The results show that dermal
exposure to both TLR4 ligand lipopolysaccharide (LPS) and
TLR2 ligand Pam3Cys suppresses asthmatic responses, when
given at the time of sensitization, by reducing airway hyper-
reactivity (AHR), Th2-type inflammation, and IgE antibodies in
a dose-dependent manner. On the other hand, TLR3 ligand
Poly(I:C) was not able to protect the mice from asthmatic
parameters in general but reduced IgE and induced IgG2a
concentrations in serum. The protecting effect of TLR4 ligand
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LPS was found to be due to an enhanced production of IFN-g
in the airways.
RESULTS
Dermal exposure to TLR ligands decreases allergic inflammation
and AHR
Mice were sensitized intradermally with PBS, OVA, and OVA
in combination with low (1mg) or high (10mg) doses of TLR
ligands Pam3Cys (TLR2), poly(I:C) (TLR3), and LPS (TLR4)
once a week for 4 weeks (Figure 1a). Samples were analyzed
after three intranasal ovalbumin (OVA) challenges. High doses
of LPS or Pam3Cys significantly attenuated airway responsive-
ness to metacholine (MCh), whereas Poly(I:C) had only a
minor effect on AHR (Figure 1b and Supplementary Figure S1
online). Low doses of TLR ligands had no effect on airway
responses (data not shown). The total number of cells and
inflammatory cells in bronchoalveolar lavage (BAL) fluid were
significantly reduced after LPS and Pam3Cys treatments,
whereas Poly(I:C) had no effect (Figure 1c). The number of
eosinophils was significantly reduced with all three ligands
(Figure 1d), whereas no significant differences were detected
in the number of neutrophils or lymphocytes (data not shown).
Very high doses (100mg) of Poly (I:C) induced the recruitment
of significantly higher numbers of eosinophils and lympho-
cytes in BAL fluid (Supplementary Figure S2 online).
PASþ cells were reduced dose dependently with each
ligand tested, although the effect showed statistical signifi-
cance only with LPS (Figure 1e and Supplementary Figure S3
online). In addition, LPS treatment significantly decreased the
number of F4/80-positive macrophages in the lungs (Figure 1f
and Supplementary Figure S3 online). Instead, the number of
CD3þ T cells showed no change with any of the TLR ligands
tested (Figure 1g and Supplementary Figure S3 online). All TLR
agonists significantly enhanced serum OVA–specific IgG2a at
high doses, and the effect was dose dependent (Figure 1h).
In addition, both low and high doses of each TLR ligand
significantly decreased OVA-specific IgE (Figure 1i).
TLR ligands decrease Th2 cytokines in the lung and in draining
lymph nodes (LNs)
Dermal administration of LPS and Pam3Cys decreased the
expression of Th2-type cytokines IL-4, IL-5, and IL-13 as well
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Figure 1. The effects of intradermal (i.d.) administration of Toll-like receptor (TLR) ligands on the lung inflammatory response. (a) The study protocol.
(b) Lung resistance (RL) and (c, d) the total number of cells and eosinophils in bronchoalveolar lavage (BAL) fluid. (e) Periodic acid-Schiff (PAS) staining of
mucus-producing cells. Results are indicated as the average of PASþ cells per 200mm of bronchus surface. Number of immunohistochemically stained (f) F4/80þ
antigen-presenting cells (APCs) and (g) CD3þ cells in the lungs counted as an average from five randomly selected areas. TLR ligands upregulated (h) ovalbumin
(OVA)-specific IgG2a and downregulated (i) OVA-specific IgE antibodies in the serum, as measured with ELISA. Results are presented as absorbance units
(405 nm). *P, 0.05; **P, 0.01; ***P, 0.001. n¼8 mice per group. AHR, airway hyperreactivity; HPF, high power field; i.n., intranasally; LPS, lipopolysaccharide;
OD, optical density; PBS, phosphate-buffered saline.
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as that of pro-Th2-type IL-33 in lung tissue (Figure 2a and b).
The most drastic reductions were seen with both doses of LPS
and with 10mg of Pam3Cys. The expression of IL-13 was
significantly lower at the protein level in OVA-stimulated LNs
after LPS or Pam3Cys treatment (Supplementary Figure S4
online). On the contrary, Poly(I:C) treatment at three different
doses (1, 10, and 100mg) showed no change in the expression
of Th2-type cytokines in the lung (Figure 2a, Supplementary
Figure S2 online).
When analyzing Th1 cytokines, LPS was the only ligand
eliciting a significant increase in IFN-g mRNA in the lung
tissue (Figure 2c). The expression of IL-12 showed no change
with any of the three TLR ligands (data not shown).
Regulatory T cells are not involved in the attenuation of
asthmatic responses
Involvement of regulatory T cells (Tregs) in mediating toler-
ance and suppressive function in asthma has been well
characterized (Lloyd and Hawrylowicz, 2009). Mice treated
with OVA and LPS exhibited significantly lower amounts of
Foxp3 mRNA in lung tissue when compared with mice treated
with OVA alone, whereas other TLR ligands had no effect
(Figure 3a). Expression of IL-10 was downregulated after
dermal exposure to both doses of LPS and to the high dose
of Pam3Cys (Figure 3b). All TLR ligands also significantly
reduced CTLA-4, a negative regulator of immune response, in
the lung tissue. The most drastic reduction was observed with
LPS (Po0.001) when compared with either Pam3Cys
(P40.01) or Poly(I:C) (Po0.05) (Figure 3c). Instead, a small
but significant increase in the expression of CD40 and major
histocompatibility complex II (MHCII) on lung CD11bþ cells
was detected (Supplementary Figure S5 online).
Cutaneous exposure to TLR ligands modifies the function of
dendritic cells (DCs) during sensitization
To understand the early events in dermal sensitization, we
analyzed the function and number of DCs in draining LNs
24 hours after administration of OVA-Alexa647. Activated
DCs (CD11cþOVAþ ) showed 20% enhanced cell adhesion
and cell proliferation (CD40), 32–42% enhanced costimula-
tion (CD80, CD86), and 17% enhanced antigen presentation
(MHCII) when compared with resting DCs (CD11cþOVA )
(Supplementary Figure S6 online). Among OVAþ DCs,
dermal exposure to both LPS and Pam3Cys reduced the total
number of OVAþ CD11cþ DCs in draining LNs in a dose-
dependent manner (Figure 4a). LPS enhanced the expression
of activation markers CD80 and CD86, whereas no differ-
ences in MHCII were detected with any of the TLR ligands
(Figure 4b–d).
Next, we conducted a kinetic study using dermal injections
of OVA and OVA with 10mg of LPS. After testing at all time
points (2–48 hours), the percentage of OVAþ DCs in the
draining LNs of the skin was found to be lower in mice
receiving OVA and LPS when compared with the group given
OVA alone (Figure 4e). In contrast, the expression levels of
surface activation markers, CD80 and CD86, were clearly
enhanced in mice given OVA and LPS, and the effect lasted
from 2 to 48 hours (Figure 4f and g). No differences were
detected in the expression of MHCII at any time point
(Figure 4h).
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Figure 2. The expression of Th1, Th2, and proinflammatory cytokines at the RNA level in the lung after Toll-like receptor (TLR) ligand exposures. (a) Relative
amounts of Th2-type cytokine RNAs IL-4, IL-5, and IL-13, and (b) the amount of pro-Th2-type cytokine IL-33 in lung tissue. (c) The amount of mRNA of Th1-type
IFN-g in the lungs. All cytokines are determined by reverse transcriptase–PCR as relative units (RU). *P, 0.05; **P, 0.01; ***P, 0.001. n¼8 mice per group. LPS,
lipopolysaccharide; OVA, ovalbumin; PBS, phosphate-buffered saline.
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IFN-c is central to the protective effects of LPS
Dermal exposure of mice to OVA and LPS or Pam3Cys had no
effect on the number of CD4þ T cells in BAL fluid (Figure 5a);
however, a slight but insignificant enhancement in the
production of IFN-g and IL-13 from CD4þ T cells in the
OVA and LPS group was detected (Figure 5b and c). Interest-
ingly, the number of CD8þ T cells and their IFN-g production
were significantly enhanced after dermal exposure of mice to
OVA and LPS (Figure 5d and e) along with a slight but non-
significant increase in the total number of T cells in BAL fluid
(Supplementary Figure S7 online). In addition, a slight increase
was observed in the expression of CD69 of CD8þ T cells
(Figure 5f) in BAL fluid.
To assess the role of CD8þ T cells in mediating the effect of
LPS, we depleted the mice of CD8þ T cells with anti-mouse
CD8 mAb injections before OVA challenge. Instead of
reversing the protective effect of LPS, the depletion of CD8þ
T cells resulted in further reduction in Th2-type cytokines in
the lung tissue and in the numbers of eosinophils in the BAL
fluid compared with mice treated with OVA (Supplementary
Figure S8 online).
To investigate the role of IFN-g in mediating the effect of
LPS, we treated the mice with anti-mouse IFN-g mAb
injections before the OVA airway challenge. Neutralization
of IFN-g resulted in significantly reduced IFN-g mRNA levels
in the lung tissue (Figure 6a), along with increased Th2-type
cytokines IL-5 and IL-13 (Figure 6b and c), and increased
numbers of eosinophils in the BAL fluid (Figure 6d), compared
with mice treated with OVAþ LPS or with control IgG. Anti-
IFN-g mAb treatment also induced an influx of neutrophils
(Figure 6e) and lymphocytes in BAL fluid (Figure 6f) but had no
effect on mucus production or airway reactivity (data not shown).
DISCUSSION
Recent PARSIFAL and GABRIELA studies show that children
who live on farms have lower prevalence of asthma and atopy
and are exposed to a greater variety of environmental micro-
organisms compared with children in the reference group (Ege
et al., 2011). Atopic dermatitis (AD) may precede asthma
during childhood according to the ‘‘atopic march’’ (Spergel,
2005), which suggests that cutaneous sensitization and skin
inflammation are important for the development of asthma
later in life. In addition, mutations in the filaggrin gene, which
has an important role in skin barrier function, have been
shown to associate with asthma in AD patients (Batchelor
et al., 2010). Experimental sensitization is most efficient
when the antigen is administered through skin instead of
intraperitoneally (Lehto et al., 2005). Microbial components
are recognized by TLRs that initiate inflammatory responses
(Iwasaki and Medzhitov, 2004). In this study, we investigated
the role of three TLR ligands, LPS, Pam3Cys, and Poly(I:C), in
the development of asthma by mimicking the natural route of
sensitization from skin to asthmatic symptoms. We show that
dermal administration of TLR4 ligand LPS during allergen
sensitization protected the mice from asthma and airway
inflammation by reducing AHR, BAL cell number, eosinophi-
lia, mucus formation, and systemic IgE concentration. TLR2
agonist Pam3Cys also effectively reduced Th2-type inflam-
matory responses, whereas TLR3 ligand Poly(I:C) had a
minimal effect on local asthmatic parameters.
Allergic asthma is usually linked to enhanced Th2 res-
ponses, including increased number of eosinophils, mucus
overproduction, and AHR. In addition, Th2-type cytokines,
such as IL-4, IL-5, and IL-13, contribute to the induction and
maintenance of airway inflammation and asthmatic response.
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Figure 3. The effect of Toll-like receptor (TLR) ligands on lung regulatory
factors at the RNA levels after 4 weeks of sensitization. The relative
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OVA, ovalbumin; PBS, phosphate-buffered saline.
R Haapakoski et al.
TLRs in Asthma
www.jidonline.org 967
IL-5 is known to have a pivotal role as a major maturation and
differentiation factor for eosinophils (Takatsu et al., 2009),
whereas IL-13 has been shown to directly contract airway
smooth muscle cells and thus enhance the development of
AHR (Kuperman et al., 2002; Akbari et al., 2003). In our
model, dermal exposure to LPS, especially, and also to
Pam3Cys, significantly reduced the production of IL-4, IL-5,
and IL-13 in the lungs and that of IL-13 in draining LNs. We
therefore hypothesize that IL-13, which is highly produced by
lung eosinophils, is related to the significant reduction of
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eosinophils by LPS or Pam3Cys treatment. This result is
supported by decreased mucus production in concert with
reduced production of IL-4 and IL-5. Further analysis showed
that expression levels of regulatory transcription factor Foxp3,
cytokine IL-10, and inhibitory marker CTLA-4 were decreased
especially after LPS treatment. Therefore, our findings strongly
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suggest that the inhibition of allergic responses could not be a
result of an induced amount or function of regulatory T cells
but instead because of a decreased amount of eosinophils in
the lungs.
Endotoxin tolerance (ET) or TLR tolerance is a phenomenon,
where repeated systemic application of LPS or other TLR
ligands can induce a state of immune unresponsiveness (Broad
et al., 2007; Biswas and Lopez-Collazo, 2009). Matsushita
et al. (2010) suggest that the downregulated expression of
MHC class II and costimulatory molecules, CD86 and CD40,
on DCs and monocytes is a good biomarker for ET in vivo.
However, we saw a small but significant increase instead of
a reduction in the expression of CD40 and MHCII on lung
CD11cþ and CD11bþ cells after 4 weeks of sensitization and
elicitation. This advocates that TLR tolerance does not explain
the decreased asthma symptoms in this model.
TLR ligands are potent activators of DCs resulting in the
initiation of adaptive immunity. In our study, dermal admin-
istration of TLR ligands during allergen sensitization decreased
the number of antigen-bearing DCs in LNs but enhanced their
activation status. DCs that engulfed OVA or OVA and LPS had
similar kinetics, and they traveled into draining LNs peaking
by 4 hours after antigen administration. However, their
number was decreased in the LPS-treated groups at all time
points tested, maybe because of a decreased intrinsic migra-
tory ability as described by Granucci et al. (1999). In addition,
LPS is shown to accelerate the maturation and redistribution of
DCs followed by a marked decrease in DC numbers, unless a
signal is received from Ag-specific T cells (De Smedt et al.,
1996, 1998). DCs that survived through the OVA and LPS
treatment in our study maintained a high antigen presentation
capacity (MHCII), and activation by a highly increased
expression of CD80 and a less increased expression of
CD86. CD86 is linked to Th2 development, whereas CD80
might be a more Th1-type or neutral costimulatory molecule
(Kuchroo et al., 1995; Moser and Murphy, 2000).
Exposure to household endotoxins during childhood is
inversely related to allergen sensitization (Gereda et al.,
2000) and to the development of allergic asthma (Braun-
Fahrla¨nder et al., 2002). The mechanisms that drive immunity
after endotoxin or LPS exposure are multifactorial and partly
unknown. LPS can support the development and function of
the major T-cell subsets depending on the situation, which has
led to a re-evaluation of its effects on adaptive immunity
(McAleer and Vella, 2010). In our study, when comparing the
OVA and LPS group with the OVA group after 4 weeks of
sensitization, the number of CD8þ T cells in BAL fluid was
seen to have increased significantly, whereas the number of
CD4þ T cells had remained unchanged. T cells in OVA- and
LPS-treated mice produced significantly more IFN-g because
of increased numbers of CD8þ T cells, and these cells were
also more active as indicated by the expression of CD69.
However, in vivo depletion of CD8þ T cells did not reverse
the protective effect of LPS but instead led to further decreased
numbers of eosinophils and reduction of Th2-type cytokines in
the lung, likely a consequence of depleting the entire
compartment of CD8þ T cells, including Th2-like CD8þ T
cells, which are known to mediate airway inflammation and
AHR (Miyahara et al., 2004; Stock et al., 2004). Nevertheless,
in vivo neutralization of IFN-g demonstrated a clear
dependence of the protective effect of LPS on IFN-g.
To the best of our knowledge, no other report has studied
the early events of LPS directly in vivo in similar study settings.
In one study, low-dose LPS-pulsed bone marrow–derived DCs
caused massive eosinophilia and enhanced Th2 cytokine
production in mice, whereas high-dose LPS-induced Th17-
type immune responses and LPS-free OVA did not induce
allergic symptoms at all (Peters et al., 2010). Depending
on the local microenvironment, T cells might be polarized
from Th2 to Th1, Th17, or to Treg cells. Treatment with TLR
agonists during the challenge before or after allergen exposure
has produced quite different outcomes (Duechs et al., 2011).
We have previously shown enhanced Th1 polarization
after dermal TLR9 ligand CpG exposure during allergen
sensitization. (Haapakoski et al., 2011). Here we show that
identical exposure regimes of different TLR ligands exhibit
various effects on the Th2 inflammatory response. TLR2 and
TLR4 agonists induced protective effects, whereas TLR3
agonist poly I:C had no effect at low concentrations and
augmented the Th2-type response at high concentrations. The
different outcomes might be the result of the distinct signaling
pathways used by the TLRs, with TLR3 utilizing exclusively
the TRIF-dependent pathway and TLR2 and TLR4 signal
utilizing the MyD88-dependent pathways as well (Akira
et al., 2006). The various responses mediated by TLRs likely
evolved to fine-tune adaptive immunity, and different dose,
time, and administration routes elicit qualitatively distinct
signals through TLRs, influencing T-cell polarization.
According to the hygiene hypothesis, the increase in atopy
and asthma is related to improved hygiene status and reduced
Th1-type immune responses in the industrialized world (Yang
and Gao, 2011). Endotoxins and other bacterial derivatives
present in the environment are suggested to have a role in the
process by affecting DC maturation and T-cell polarization by
favoring the development of protective immunity. Our results
show that allergen sensitization through skin with LPS and
Pam3Cys, but not with Poly(I:C), decreases Th2-type allergic
responses and airway reactivity. TLR4 ligand LPS was the
only ligand to shift the balance toward Th1-type immunity
by inducing IFN-g production from CD8þ T cells and by
reducing Th2-type cytokines. The suppressive effect was
strictly dependent on IFN-g. These findings shed light on the
interaction of innate immunity-activating microbial com-
ponents and the dermal route of sensitization during allergic
inflammation. Our results emphasize the importance of
restoring the skin barrier function and also highlight the role
of cross-talk between the dermal microbiome and the host in
the development of allergies.
MATERIALS AND METHODS
Mice
Female Balb/c mice (NOVA-SCB AB, Sollentuna, Sweden) aged
6–8 weeks were maintained on OVA-free diets and water
ad libitum. All animal experiments were approved by The Social
and Health Care Department of the State Provincial Office of
Southern Finland.
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Ultra Pure E. coli LPS (strain 0111:B4, #06B24-MT) and High
Molecular Weight Poly(I:C) (endotoxin level o1.25 EU/ml, #09L02-
MT) were purchased from InvivoGen (San Diego, CA). Pam3Cys
(PamCys-SKKKK, L2000) was purchased from EMC microcollections
GmbH (Tu¨bingen, Germany).
Treatment protocols
Mice were anesthetized and their backs were shaved and tape-
stripped three times before the injections to introduce the skin injury.
The mice were sensitized weekly intradermally with 50mg of OVA in
100ml, or with PBS only for 4 weeks. Groups of mice were treated
with 1mg or 10mg of LPS concurrent with 50mg of OVA (OVA and
LPS groups), with 1mg or 10mg of Pam3Cys (OVA and Pam3Cys
groups), or with 1mg, 10mg, or 100mg of Poly(I:C) (OVA and Poly(I:C)
groups). On days 28, 29, and 30 all mice were challenged with
intranasal OVA (50mg OVA in 50ml of PBS).
For kinetic studies, the backs of the mice were shaved and tape
stripped three times, and they were treated either with 50mg of OVA-
Alexa647 (Invivogen, San Diego, CA) alone or in combination with
10mg of each TLR ligand intradermally. After different time points
(0, 2, 4, 6, 9, 24, and 48 hours), the mice were killed and the draining
LNs were collected for FACS analysis.
CD8 T cells were depleted by 200mg of anti-mouse CD8 mAb
intraperitoneally 4, 2, and 1 day before the 3-day OVA elicitation
period. Control mice were treated with the same amount of rat IgG2.
IFN-g was neutralized by 200mg of anti-mouse IFN-g mAb or control
IgG1 mAb intraperitoneally on day 27 (1 day before the OVA airway
challenge) and again three times intranasally (50mg of anti-IFN-g Ab
or IgG1 together with 50mg of OVA) on days 28, 29, and 30.
Determination of airway reactivity to methacholine
Airway resistance and compliance were measured from sensitized
and challenged mice as previously described (Haapakoski et al., 2011).
BAL and lung histology
BAL inflammatory cells and lung histology were handled and counted
as previously described (Haapakoski et al., 2011).
RT-PCR analysis
Total RNA extractions with Trisure Reagent (Bioline, London, UK),
complementary DNA synthesis, and real-time PCR (RT-PCR) were
performed as previously described (Lehto et al., 2003).
Measurement of cytokines by ELISA and flow cytometry
The cytokine levels of IL-13 were measured by ELISA from BAL fluids
and from supernatants of cultured LN and from splenocytes according
to the manufacturer’s instructions (R&D Systems, Minneapolis, MN
for IL-13). The detection limit was 8 pg ml 1.
Flow cytometric analyses
BAL cells were washed once with PBS/2% FBS; Fc receptors were
blocked with anti-mouse CD16/32 (eBioscience, San Diego, CA); and
cells were stained with anti-TCRb, anti-CD3, anti-CD4, and anti-CD8
antibodies (BD Pharmingen, San Diego, CA). For intracellular
cytokines, BAL cells were stimulated at 37 1C for 4 hours with phorbol
myristate acetate (20 ng ml 1) and ionomycin (1 mg ml 1) (Sigma,
St. Louis, MO), including brefeldin A (Sigma). After washing,
Fc blocking, and surface staining, cells were permeabilized using
the Fix and Perm kit (Caltag, Burlingame, CA) and stained with anti-
IFN-g (BD Pharmingen) and anti-IL-13 (eBioscience).
For kinetic studies, brachial LNs were removed, teased with glass
slides, and filtered through a 70-mm cell strainer; thereafter, the total
number of cells was counted. Single-cell suspensions were Fc
blocked, stained with mAbs for CD11c, CD11b, MHCII, CD40,
CD80, and CD86 (eBioscience), and run on a FACSCantoII instru-
ment (Becton Dickinson, Franklin Lakes, NJ). Data were processed
using FlowJo Software (Tree Star, Ashland, OR).
Measurement of serum antibodies
OVA-specific IgE and IgG2a antibodies were measured from serum
using ELISA as previously described (Lehto et al., 2003).
Statistics
Single-group comparisons were made using the nonparametric
Mann–Whitney U-test. Results are expressed as mean±SEM and
P-values of o0.05 were considered statistically significant. Statistical
analyses were performed using GrapPadPrism (version 4 GraphPad
Software, La Jolla, CA).
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
We thank Sauli Savukoski for his expertise in immunohistological work. We
also thank Pa¨ivi Alander and Santtu Hirvikorpi for their excellent technical
assistance. This research was funded by the Academy of Finland, by the
European Union’s FP7, grant agreement number HEALTH-F2-2011-261366,
and by the Nummela Foundation.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper at http://
www.nature.com/jid
REFERENCES
Akbari O, Stock P, Meyer E et al. (2003) Essential role of NKT cells producing
IL-4 and IL-13 in the development of allergen-induced airway hyperreac-
tivity. Nat Med 9:582–8
Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate
immunity. Cell 124:783–801
Bach JF (2002) The effect of infections on susceptibility to autoimmune and
allergic diseases. N Engl J Med 347:911–20
Batchelor JM, Grindlay DJ, Williams HC (2010) What’s new in atopic eczema?
An analysis of systematic reviews published in 2008 and 2009. Clin Exp
Dermatol 35:823–7
Biswas SK, Lopez-Collazo E (2009) Endotoxin tolerance: new mechanisms,
molecules and clinical significance. Trends Immunol 30:475–87
Braun-Fahrla¨nder C, Riedler J, Herz U et al. (2002) Environmental exposure to
endotoxin and its relation to asthma in school-age children. N Engl J Med
347:869–77
Broad A, Kirby JA, Jones DE (2007) Toll-like receptor interactions: tolerance of
MyD88-dependent cytokines but enhancement of MyD88-independent
interferon-beta production. Immunology 120:103–11
Cohn L, Elias JA, Chupp GL (2004) Asthma: mechanisms of disease persistence
and progression. Annu Rev Immunol 22:789–815
De Smedt T, Pajak B, Klaus GG et al. (1998) Antigen-specific T lymphocytes
regulate lipopolysaccharide-induced apoptosis of dendritic cells in vivo.
J Immunol 161:4476–9
De Smedt T, Pajak B, Muraille E et al. (1996) Regulation of dendritic cell numbers
and maturation by lipopolysaccharide in vivo. J Exp Med 184:1413–24
R Haapakoski et al.
TLRs in Asthma
www.jidonline.org 971
Duechs MJ, Hahn C, Benediktus E et al. (2011) TLR agonist mediated
suppression of allergic responses is associated with increased innate
inflammation in the airways. Pulm Pharmacol Ther 24:203–14
Ege MJ, Mayer M, Normand AC et al. (2011) Exposure to environmental
microorganisms and childhood asthma. N Engl J Med 364:701–9
Ernst P, Cormier Y (2000) Relative scarcity of asthma and atopy among rural
adolescents raised on a farm. Am J Respir Crit Care Med 161:1563–6
Gereda JE, Leung DY, Thatayatikom A et al. (2000) Relation between house-
dust endotoxin exposure, type 1 T-cell development, and allergen
sensitisation in infants at high risk of asthma. Lancet 355:1680–3
Granucci F, Ferrero E, Foti M et al. (1999) Early events in dendritic cell
maturation induced by LPS. Microbes Infect 1:1079–84
Haapakoski R, Karisola P, Fyhrquist N et al. (2011) Intradermal cytosine-
phosphate-guanosine treatment reduces lung inflammation but induces
IFN-{gamma}-mediated airway hyperreactivity in a murine model of
natural rubber latex allergy. Am J Respir Cell Mol Biol 44:639–47
Holloway JW, Yang IA, Holgate ST (2010) Genetics of allergic disease.
J Allergy Clin Immunol 125:S81–94
Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive
immune responses. Nat Immunol 5:987–95
Kuchroo VK, Das MP, Brown JA et al. (1995) B7-1 and B7-2 costimulatory
molecules activate differentially the Th1/Th2 developmental pathways:
application to autoimmune disease therapy. Cell 80:707–18
Kuperman DA, Huang X, Koth LL et al. (2002) Direct effects of interleukin-13
on epithelial cells cause airway hyperreactivity and mucus overproduc-
tion in asthma. Nat Med 8:885–9
Lehto M, Haapakoski R, Wolff H et al. (2005) Cutaneous, but not airway, latex
exposure induces allergic lung inflammation and airway hyperreactivity
in mice. J Invest Dermatol 125:962–8
Lehto M, Koivuluhta M, Wang G et al. (2003) Epicutaneous natural rubber
latex sensitization induces T helper 2-type dermatitis and strong prohe-
vein-specific IgE response. J Invest Dermatol 120:633–40
Lloyd CM, Hawrylowicz CM (2009) Regulatory T cells in asthma. Immunity
31:438–49
Masoli M, Fabian D, Holt S et al. (2004) The global burden of asthma:
executive summary of the GINA Dissemination Committee report. Allergy
59:469–78
Matsushita H, Ohta S, Shiraishi H et al. (2010) Endotoxin tolerance attenuates
airway allergic inflammation in model mice by suppression of the T-cell
stimulatory effect of dendritic cells. Int Immunol 22:739–47
McAleer JP, Vella AT (2010) Educating CD4 T cells with vaccine adjuvants:
lessons from lipopolysaccharide. Trends Immunol 31:429–35
Miyahara N, Swanson BJ, Takeda K et al. (2004) Effector CD8þ T cells mediate
inflammation and airway hyper-responsiveness. Nat Med 10:865–9
Moser M, Murphy KM (2000) Dendritic cell regulation of TH1-TH2 develop-
ment. Nat Immunol 1:199–205
Peters M, Dudziak K, Stiehm M et al. (2010) T-cell polarization depends on
concentration of the danger signal used to activate dendritic cells.
Immunol Cell Biol 88:537–44
Reijmerink NE, Bottema RW, Kerkhof M et al. (2010) TLR-related pathway
analysis: novel gene-gene interactions in the development of asthma and
atopy. Allergy 65:199–207
Spergel JM (2005) Atopic march: link to upper airways. Curr Opin Allergy Clin
Immunol 5:17–21
Stock P, Kallinich T, Akbari O et al. (2004) CD8(þ ) T cells regulate immune
responses in a murine model of allergen-induced sensitization and airway
inflammation. Eur J Immunol 34:1817–27
Strachan DP (1989) Hay fever, hygiene, and household size. BMJ
299:1259–60
Takatsu K, Kouro T, Nagai Y (2009) Interleukin 5 in the link between the innate
and acquired immune response. Adv Immunol 101:191–236
Tesse R, Pandey RC, Kabesch M (2011) Genetic variations in toll-like receptor
pathway genes influence asthma and atopy. Allergy 66:307–16
von Mutius E, Vercelli D (2010) Farm living: effects on childhood asthma and
allergy. Nat Rev Immunol 10:861–8
Yang X, Gao X (2011) Role of dendritic cells: a step forward for the hygiene
hypothesis. Cell Mol Immunol 8:12–8
R Haapakoski et al.
TLRs in Asthma
972 Journal of Investigative Dermatology (2013), Volume 133
